Literature DB >> 33872769

Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent.

Olivier Vollmer1, Charles Tacquard2, Yannick Dieudonné1, Benoit Nespola3, Laurent Sattler4, Lélia Grunebaum4, Vincent Gies1, Mirjana Radosavljevic3, Charlotte Kaeuffer5, Yves Hansmann5, Jean-Christophe Weber6, Thierry Martin1, Laurent Arnaud7, Olivier Morel8, Aurélien Guffroy1, Olivier Collange2, Paul Michel Mertes2, Anne-Sophie Korganow1, Xavier Delabranche2, Vincent Poindron9.   

Abstract

Entities:  

Keywords:  APS; Anti-phospholipid antibodies; COVID-19; Lupus anticoagulant; SARS-CoV-2; Thrombosis

Year:  2021        PMID： 33872769     DOI： 10.1016/j.autrev.2021.102822

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN： 1568-9972            Impact factor:   9.754


× No keyword cloud information.
  9 in total

Review 1.  Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy.

Authors:  Manuel Serrano; Gerard Espinosa; Antonio Serrano; Ricard Cervera
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

Review 2.  COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors.

Authors:  Daniele Focosi; Massimo Franchini; Liise-Anne Pirofski; Thierry Burnouf; DeLisa Fairweather; Michael J Joyner; Arturo Casadevall
Journal:  Viruses       Date:  2021-08-11       Impact factor: 5.818

Review 3.  Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome.

Authors:  Martin Killian; Thijs E van Mens
Journal:  Front Cardiovasc Med       Date:  2022-03-01

4.  Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins.

Authors:  Marc Emmenegger; Sreedhar Saseendran Kumar; Vishalini Emmenegger; Tomas Malinauskas; Thomas Buettner; Laura Rose; Peter Schierack; Martin F Sprinzl; Clemens J Sommer; Karl J Lackner; Adriano Aguzzi; Dirk Roggenbuck; Katrin B M Frauenknecht
Journal:  PLoS Pathog       Date:  2021-12-03       Impact factor: 6.823

5.  Assessment of antiphospholipid antibodies profiles based on severity of COVID-19 pneumonia.

Authors:  Amène Ben Bnina; Refka Ben Dhia; Sahar Gnaba; Alaa Annabi; Syrine Chouchane; Walid Naija; Houyem Said; Abderraouf Oueslati; Amina Bouatay
Journal:  Pan Afr Med J       Date:  2022-06-09

6.  Assessment of COVID -19 associated coagulopathy and multiple hemostatic markers: a single center study in Egypt.

Authors:  Azza Abdelaal; Ahmed Abu-Elfatth; Lamees M Bakkar; Hanan G Abd El-Azeem; Helal F Hetta; Eman R Badawy
Journal:  Infection       Date:  2022-09-22       Impact factor: 7.455

7.  Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?

Authors:  Thomas Foret; Virginie Dufrost; Lucie Salomon Du Mont; Patricia Costa; Benjamin Lefevre; Patrick Lacolley; Veronique Regnault; Stephane Zuily; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2021-07-03       Impact factor: 4.592

8.  Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort.

Authors:  Tingting Liu; Jing Dai; Zhitao Yang; Xiaoqi Yu; Yanping Xu; Xinming Shi; Dong Wei; Zihan Tang; Guanqun Xu; Wenxin Xu; Yu Liu; Ce Shi; Qi Ni; Chengde Yang; Xinxin Zhang; Xuefeng Wang; Erzhen Chen; Jieming Qu
Journal:  Sci Bull (Beijing)       Date:  2021-07-27       Impact factor: 11.780

Review 9.  Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19.

Authors:  Nevio Cimolai
Journal:  SN Compr Clin Med       Date:  2021-06-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.